^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Soft Tissue Sarcoma
    Drug:Yondelis (trabectedin) (Alkylating agent, DNA inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    Scottish Medicines Consortium
    Title:

    Trabectedin (Yondelis®) is accepted for use within NHSScotland.

    Published date:
    10/09/2020
    Excerpt:
    ...Treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Excerpt:
    Yondelis is indicated for the treatment of patients with advanced soft-tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    04/28/2021
    Excerpt:
    Soft Tissue Sarcoma: Useful in Certain Circumstances...Trabectedin
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Title:

    Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†

    Excerpt:
    Summary of recommendations...Trabectedin is an option for second line and beyond [I, B] and is approved for advanced previously treated STS.
    DOI:
    10.1093/annonc/mdy310